Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0917798 (
cerebral ischemia
)
17,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The function of
Epigallocatechin gallate
(
EGCG
), a main component of green tea, has been widely investigated, amelioration of synaptic transmission and neuroprotective effects against ischemia-induced brain damage among others. However, the mechanism underlying is still unveiled. We investigated the effects of
EGCG
on high frequency stimulation-induced long-term potentiation (LTP) in the Schaffer collateral-CA1 synapse with or without
cerebral ischemia
injury induced by middle cerebral artery occlusion (MCAO) in vivo to examine the possible relations between
EGCG
and synaptic transmission. Application of
EGCG
modulated synaptic transmission and produced a dose-dependent improvement of the induction of LTP. However, relative high-dose
EGCG
can block the induction of LTP at the Schaffer collateral-CA1 synapse in normal rat in vivo. In addition, the effects of
EGCG
were observed on the infarct volume and neurological deficit in rats subjected to MCAO; furthermore, the cell viability of primary cultured rat hippocampal and cortical neurons suffered from oxygen-glucose deprivation were evaluated with MTT and LDH assay, which showed significant neuroprotective properties in vitro. Surprisingly, the contents of the glutamate (Glu), glycine (Gly), and gamma-aminobutyric acid amino acids were totally disequilibrated before and after
cerebral ischemia
injury and could be rebalanced to original level by application of
EGCG
. Our results suggest that
EGCG
is able to improve the efficiency of synaptic transmission in
cerebral ischemia
injury with attenuated effect related to the neuroprotection of
EGCG
through regulating excitatory and inhibitory amino acid balance.
...
PMID:EGCG ameliorates the suppression of long-term potentiation induced by ischemia at the Schaffer collateral-CA1 synapse in the rat. 2207 75
(-)-Epigallocatechin gallate
(
EGCG
) has recently been shown to exert neuroprotection in a variety of neurological diseases; however, its role and the underlying mechanisms in cerebral ischemic injury are not fully understood. This study was conducted to investigate the potential neuroprotective effects of
EGCG
and the possible role of the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway in the putative neuroprotection against experimental stroke in rats. The results revealed that
EGCG
exhibit significant neuroprotection, as evidenced by reduced infarction size and the decrease in transferase dUTP nick end labeling-positive neurons. Furthermore,
EGCG
also enhanced levels of Nrf2 and its downstream ARE pathway genes such as heme oxygenase-1, glutamate-cysteine ligase modulatory subunit and glutamate-cysteine ligase regulatory subunit, as compared to control groups. In accordance with its induction of Nrf2 activation,
EGCG
exerted a robust attenuation of reactive oxygen species generation and an increase in glutathione content in ischemic cortex. Taken together, these results demonstrated that
EGCG
exerted significant antioxidant and neuroprotective effects following focal
cerebral ischemia
, possibly through the activation of the Nrf2/ARE signaling pathway.
...
PMID:(-)-Epigallocatechin gallate protects against cerebral ischemia-induced oxidative stress via Nrf2/ARE signaling. 2479 31
Cerebral ischemia
is a neurological disorder that causes permanent disability and is sometimes fatal.
Epigallocatechin gallate
(
EGCG
) is a natural polyphenol that exerts beneficial antioxidant and anti-inflammatory effects. The aim of this study was to investigate the neuroprotective effects of
EGCG
against
cerebral ischemia
. Middle cerebral artery occlusion was surgically initiated to induce focal
cerebral ischemia
in adult male rats.
EGCG
(50 mg/kg) or vehicle was intraperitoneally injected just prior to middle cerebral artery occlusion (MCAO) induction. Neuronal behavior tests were performed 24 hr after MCAO. Brain tissues were isolated to evaluate infarct volume, histological changes, apoptotic cell death, and caspase-3 and poly ADP-ribose polymerase (PARP) levels. MCAO injury led to serious functional neurological deficits and increased infarct volume. Moreover, it induced histopathological lesions and increased the numbers of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the cerebral cortex. However,
EGCG
improved MCAO-induced neurological deficits and reduced infarct volume, alleviated histopathological changes, and decreased TUNEL-positive cells in the cerebral cortex of MCAO rats. Western blot analysis showed increases of caspase-3 and PARP expression levels in MCAO rats with vehicle, whereas
EGCG
administration alleviated these increases after MCAO injury. These results demonstrate that
EGCG
exerts a neuroprotective effect by regulating caspase-3 and PARP proteins during
cerebral ischemia
. In conclusion, we suggest that
EGCG
acts as a potent neuroprotective agent by modulating the apoptotic signaling pathway.
...
PMID:Epigallocatechin gallate alleviates neuronal cell damage against focal cerebral ischemia in rats. 3222 55